
Sign up to save your podcasts
Or


David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.
By John Simboli5
77 ratings
David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.

534 Listeners

3,072 Listeners

1,091 Listeners

940 Listeners

795 Listeners

125 Listeners

322 Listeners

96 Listeners

9,942 Listeners

34 Listeners

519 Listeners

146 Listeners

349 Listeners

182 Listeners

467 Listeners